Oxford BioDynamics Plc is a biotechnology company, which engages in the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The firm is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch PSE, Specimen Submission Kit, and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test which predicts an individual patient’s therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The Specimen Submission Kit is used for collecting samples from any location. The EpiSwitch platform offers reproducibly translating three-dimensional (3D) genome regulation for clinical applications. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for OXBOF. Our analysts highlight strong fundamentals and favorable market sentiment, positioning OXBOF for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: OXBOF is a Strong Buy candidate.
OXBOF stock price ended at $0 on 星期三, after rising NaN%
On the latest trading day Jan 07, 2026, the stock price of OXBOF rose by NaN%, climbing from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. Notably, trading volume dropped by 65.7K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 175.7K shares were traded, equating to a market value of approximately --.